Blue Note Pharmaceuticals Inc.
|
|
|
|
|
lead development project is BNP 32.762; a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina | |
Korean Distributor : ??? |
Products information :
|
|
|
|
|
|
|
|
|
|